-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $66

Benzinga·07/30/2026 15:43:10
Listen to the news
Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $70 to $66.